Figure 3

Follicular activity and hormonal levels among the three participants who ovulated. (A) Patient ID 30 in the EE/GS group started medication on day seven of menstruation when the LFD was 11.8 mm, the LH level was 15.72 IU/mL, and the estradiol level was 296.67 ng/mL. Ovulation was suspected on day three after the intervention, as TVUS showed the sudden disappearance of LFD. On day eight, progesterone level rose to 13.10 ng/mL. (B) Patient ID 32 in the EE/GS group started medication on day eight of menstruation when the LFD was 16.9 mm, the LH level was 4.94 IU/mL, and the estradiol level was 277.87 ng/mL. Ovulation was suspected on day three after the intervention, as TVUS showed collapsed LFD. On day seven, progesterone level rose to 5.36 ng/mL. (C) Patient ID 36 in the DRSP group started medication on day eight of menstruation when the LFD was 11.0 mm, the LH was 4.09 IU/mL, and the estradiol level was 69.87 ng/mL. On day five following intervention, LFD was 16.3 mm, the LH level was 19.9 IU/L, and the estradiol level was 305.64 ng/mL. Ovulation was suspected on day seven after the intervention, as TVUS showed collapsed LFD. On day 12, progesterone level rose to 16.71 ng/mL. EE/GS ethinyl estradiol 0.020 mg plus gestodene 0.075 mg, DRSP 4 mg drospirenone, Day 0 starting medication day, LFD leading follicle diameter, LH Luteinizing hormone, P4 Progesterone, E2 Estradiol, TVUS transvaginal ultrasound.